<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210309050653N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-25</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of propofol and sevoflurane with and without remifentanil on anesthesia depth and hemodynamic stability</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of propofol and sevoflurane with and without remifentanil on anesthesia depth and hemodynamic stability</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54939</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: selection of samples will be with available sampling and attribution of patients to the groups will be done with random allocation software.80 patients who are going to have choleystectomy surgery according to main and inclusion criteria will be considered.patients will be claassified to four group with random allocation software.And it would be clarified that number one or number ten patient should be in which one of these groups and which drug they should recieve, Blinding description: patients are not aware of type of anesthesia drugs.and the anesthesiologist who manages aneshesia is not aware of BIS values and he manages depth of anesthesia according to his clinical experience.</study_design>
      <phase>2-3</phase>
      <hc_freetext>anesthesia drugs.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: patients who recieve sevofluran as a maintenance anesthetic drug.In this group,patients will recieve sevofluran with the dose of almost 3 MAC.The anesthesiologyst may change the dose of sevofluran according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values. Intervention 2: Intervention group: patients who recieve sevofluran as a maintenance anesthetic drug.In this group,patients will recieve sevofluran with the dose of almost 3 MAC and remifentanil with the dose of 0.2 microgran/kg/min.The anesthesiologyst may change the dose of sevofluran and remifentanil according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values. Intervention 3: Intervention group: patients who recieve propofol as a maintenance anesthetic drug.In this group,patients will recieve propofol with the dose of 150 microgram/kg/min.The anesthesiologyst may change the dose of propofol according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values. Intervention 4: Intervention group: patients who recieve propofol  and remifentanil as a maintenance anesthetic drug.In this group,patients will recieve propofol with the dose of 150 microgram/kg/min and remifentanil with the dose of 0.2 microgran/kg/min .The anesthesiologyst may change the dose of propofol and remifentanil according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
some parts of data could be shared.

When:
since 1402

To whom:
university researchers

Conditions:
similar research subject

Where to obtain:
Elyas Naghib

How to obtain:
request should be with university email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elyas Naghib</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Parastar street,Hafez bulvard</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8816758915</zip>
        <telephone>+98 38 3226 4825</telephone>
        <email>elyasnaghib@yahoo.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Madineh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Parastar street,Hafez bulvard</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8816758915</zip>
        <telephone>+98 38 3226 4825</telephone>
        <email>hosseinmadineh@gmail.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>all patients with age og 15 to 65 years old
GCS of 15</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>history of addiction
BMI more than 30</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: patients who recieve sevofluran as a maintenance anesthetic drug.In this group,patients will recieve sevofluran with the dose of almost 3 MAC.The anesthesiologyst may change the dose of sevofluran according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values.</i_keyword>
      <i_keyword>Intervention group: patients who recieve sevofluran as a maintenance anesthetic drug.In this group,patients will recieve sevofluran with the dose of almost 3 MAC and remifentanil with the dose of 0.2 microgran/kg/min.The anesthesiologyst may change the dose of sevofluran and remifentanil according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values.</i_keyword>
      <i_keyword>Intervention group: patients who recieve propofol as a maintenance anesthetic drug.In this group,patients will recieve propofol with the dose of 150 microgram/kg/min.The anesthesiologyst may change the dose of propofol according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values.</i_keyword>
      <i_keyword>Intervention group: patients who recieve propofol  and remifentanil as a maintenance anesthetic drug.In this group,patients will recieve propofol with the dose of 150 microgram/kg/min and remifentanil with the dose of 0.2 microgran/kg/min .The anesthesiologyst may change the dose of propofol and remifentanil according to the patients medical condition without knowing the BIS value.The Danmeter DK-5000 device will be used for recording of BIS values.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bispectral index value. Timepoint: 5 min. Method of measurement: BIS device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-26</approval_date>
        <contact_name>Ethics committee of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>ayatollah kaashani hospital,parastar street,hafez bulvard shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
